Acetylcholinesterase triggers the aggregation of PrP 106-126

Biochemical and Biophysical Research Communications

Volumn 346, Issue 1, 2006, Pages 89-94

  Pera, M ^a   Roman S ^a   Ratia, M ^a   Camps, P ^c   Munoz Torrero D ^c   Colombo, L ^b   Manzoni, C ^b   Salmona, M ^b   Badia, A ^a   Clos, M V ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acetylcholinesterase; Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid aggregation process; Amyloid protein; Huprines; Prion protein; PrP 106 126

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; COUMARIN; HUPRINE; PRION PROTEIN; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BETA SHEET; BRIGHT FIELD MICROSCOPY; ELECTRON MICROSCOPY; HIPPOCAMPUS; MEDICAL ASSESSMENT; MOLECULAR PROBE; NERVE CELL CULTURE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; SENILE PLAQUE;

EID: 33744995785     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.187     Document Type: Article

References (34)

1. Tateishi J., Kitamoto T., Hashiguchi H., and Shii H. Gerstmann-Straussler-Scheinker disease: immunohistological and experimental studies. Ann. Neurol. 24 (1988) 35-40
2. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., Cohen F.E., et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90 (1993) 10962-10966
3. Prusiner S.B. Molecular biology of prion diseases. Science 252 (1991) 1515-1522
4. Hainfellner J.A., Wanschitz J., Jellinger K., Liberski P.P., Gullotta F., and Budka H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 96 (1998) 116-122
5. Schwarze-Eicker K., Keyvani K., Gortz N., Westaway D., Sachser N., and Paulus W. Prion protein (PrP(c)) promotes beta-amyloid plaque formation. Neurobiol. Aging 26 (2005) 1177-1182
6. Armstrong R.A., Lantos P.L., and Cairns N.J. Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology 21 (2001) 266-271
7. Kovacs G.G., and Budka H. Aging, the brain and human prion disease. Exp. Gerontol. 37 (2002) 603-606
8. Miyazono M., Kitamoto T., Iwaki T., and Tateishi J. Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol. 83 (1992) 333-339
9. Gohel C., Grigoriev V., Escaig-Haye F., Lasmezas C.I., Deslys J.P., Langeveld J., Akaaboune M., Hantai D., and Fournier J.G. Ultrastructural localization of cellular prion protein (PrPc) at the neuromuscular junction. J. Neurosci. Res. 55 (1999) 261-267
10. S. Petrakis, I. Paspaltsis, J. Lindstrom, T. Sklaviadis, PrPC coimmunoprecipitates with nicotinic acetylcholine receptor B4 subunit in normal human brain. First international congress of neuroprion (France) (2004).
11. Harris D.A., Lele P., and Snider W.D. Localization of the mRNA for a chicken prion protein by in situ hybridization. Proc. Natl. Acad. Sci. USA 90 (1993) 4309-4313
12. Inestrosa N.C., Alvarez A., Perez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., and Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16 (1996) 881-891
13. Alvarez A., Opazo C., Alarcon R., Garrido J., and Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272 (1997) 348-361
14. Bartolini M., Bertucci C., Cavrini V., and Andrisano V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 65 (2003) 407-416
15. Szegletes T., Mallender W.D., Thomas P.J., and Rosenberry T.L. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry 38 (1999) 122-133
16. Campos E.O., Alvarez A., and Inestrosa N.C. Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides. Neurochem. Res. 23 (1998) 135-140
17. Selvaggini C., De Gioia L., Cantu L., Ghibaudi E., Diomede L., Passerini F., Forloni G., Bugiani O., Tagliavini F., and Salmona M. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem. Biophys. Res. Commun. 194 (1993) 1380-1386
18. Tagliavini F., Prelli F., Verga L., Giaccone G., Sarma R., Gorevic P., Ghetti B., Passerini F., Ghibaudi E., Forloni G., Salmona M., Bugiai O., and Frangione B. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA 90 (1993) 9678-9682
19. De Gioia L., Selvaggini C., Ghibaudi E., Diomede L., Bugiani O., Forloni G., Tagliavini F., and Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269 (1994) 7859-7862
20. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362 (1993) 543-546
21. Thellung S., Florio T., Corsaro A., Arena S., Merlino M., Salmona M., Tagliavini F., Bugiani O., Forloni G., and Schettini G. Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126. Int. J. Dev. Neurosci. 18 (2000) 481-492
22. Thellung S., Florio T., Villa V., Corsaro A., Arena S., Amico C., Robello M., Salmona M., Forloni G., Bugiani O., Tagliavini F., and Schettini G. Apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126. Neurobiol. Dis. 7 (2000) 299-309
23. Hafiz F.B., and Brown D.R. A model for the mechanism of astrogliosis in prion disease. Mol. Cell Neurosci. 16 (2000) 221-232
24. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003) 40-60
25. Salmona M., Malesani P., De Gioia L., Gorla S., Bruschi M., Molinari A., Della V.F., Pedrotti B., Marrari M.A., Awan T., Bugiani O., Forloni G., and Tagliavini F. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem. J. 342 (1999) 207-214
26. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., and Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 228 (1992) 460-473
27. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., and Inestrosa N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40 (2001) 10447-10457
28. Villa A., Mark A.E., Saracino G.A., Cosentino U., Pitea D., Moro G., and Salmona M. Conformational polymorphism of the PrP 106-126 peptide in different environments: a molecular dynamics study. J. Phys. Chem. B Condens. Matter Mater. Surf. Interfaces. Biophys. 110 (2006) 1423-1428
29. Munoz-Ruiz P., Rubio L., Garcia-Palomero E., Dorronsoro I., Monte-Millan M., Valenzuela R., Usan P., de Austria C., Bartolini M., Andrisano V., Bidon-Chanal A., Orozco M., Luque F.J., Medina M., and Martinez A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem. 48 (2005) 7223-7233
30. Berman H.A., and Leonard K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Mol. Pharmacol. 41 (1992) 412-418
31. Ariel N., Ordentlich A., Barak D., Bino T., Velan B., and Shafferman A. The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem. J. 335 (1998) 95-102
32. Badia A., Baños J.E., Camps P., Contreras J., Görbigb D.M., Muñoz-Torrerob D., Simón M., and Vivas N.M. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcolinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 6 (1998) 427-440
33. Camps P., El Achab R., Gorbic D.M., Morral J., Muñoz-Torrero D., Badia A., Baños J.E., Vivas N.M., Barril X., Orozco M., and Luque F.J. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem. 42 (1999) 3227-3242
34. Camps P., Cusack B., Mallender W.D., El Achab R.E., Morral J., Munoz-Torrero D., and Rosenberry T.L. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol. Pharmacol. 57 (2000) 409-417